Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Chief Patient Officer | August 21, 2026 | August 25, 2026 |
| Enliven Therapeutics, Inc.IMRA · Entity 4024 | Director | June 02, 2022 | June 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date August 21, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 367,456 |
Ending reported balance
After 2026-08-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-21 · Sale · Disposed 3,486 · Balance 374,709 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 2 · 2026-08-21 · Sale · Disposed 3,089 · Balance 371,620 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2026-08-21 · Sale · Disposed 2,430 · Balance 369,190 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 4 · 2026-08-21 · Sale · Disposed 1,734 · Balance 367,456 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Enliven Therapeutics, Inc.
Report date June 02, 2022 · Filed June 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2032-06-01 | Direct | 8,500 |
Reported balance
After 2022-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-02 · Grant · Acquired 8,500 · Balance 8,500 F1: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 22, 2022 Filed Nov 23, 2022 21:13 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 33 | $1.95 | $64.19 |
DisclosureSEC source: 0001567619-22-020844 · doc1.xml · nonDerivative · entry 2 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,393 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:13 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 15 | $1.94 | $29.12 |
DisclosureSEC source: 0001567619-22-020844 · doc1.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,426 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| August 31, 2022 Filed Sep 1, 2022 23:03 UTC | ARDELYX, INC. ARDX · Entity 4972 | PurchaseCommon Stock | 3,000 | $0.62 | $1,856.40 |
DisclosureSEC source: 0001567619-22-016957 · doc1.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,441 F1 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan on August 31, 2022. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 21:42 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 13 | $0.98 | $12.74 |
DisclosureSEC source: 0001567619-22-016642 · doc1.xml · nonDerivative · entry 2 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,441 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 21:42 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 1,263 | $0.98 | $1,242.41 |
DisclosureSEC source: 0001567619-22-016642 · doc1.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,454 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| June 02, 2022 Filed Jun 4, 2022 00:22 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001209191-22-034392 · doc4.xml · derivative · entry 1 Williams Laura A · CIK 0001869194 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2032-06-01 F1 · derivative.exercise_date: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 21:18 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Options (Right to Buy) · Derivative | 15,457 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001209191-21-043999 · doc4.xml · derivative · entry 1 Williams Laura A · CIK 0001869194 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,457 Underlying: Common Stock · 15,457 shares Expires 2031-06-28 F1 · derivative.exercise_date: The option vests in three equal installments on June 29, 2022, 2023 and 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.